allitinib

Allitinib (AST-1306) is an orally bioavailable, potent, and selective irreversible inhibitor of the HER family of receptor tyrosine kinases. It targets epidermal growth factor receptor (EGFR; ErbB1) and human epidermal growth factor receptor 2 (HER2; ErbB2), including wild-type EGFR and resistant EGFR mutants. Allitinib has demonstrated inhibition of enzymatic activity in both cell-free and cell-based systems, leading to suppression of tumor growth in preclinical models such as ErbB2-overexpressing adenocarcinoma xenografts and transgenic breast cancer mouse models. The drug is under clinical investigation for the treatment of advanced solid tumors[4][5].